Cart

Unlocking potential with the best learning and research solutions

Look Inside Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances

Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
NEPTUNE Clinical Guidance

$79.99 (M)

Authors:
Dima Abdulrahim, Programme Manager and Principal Researcher for the NEPTUNE Project, Central and North West London NHS Foundation Trust
Owen Bowden-Jones, Consultant Addiction Psychiatrist, Central and North West London NHS Foundation Trust

Date Published: October 2022
availability: Available
format: Paperback
isbn: 9781009182133

Rate & review

$ 79.99 (M)
Paperback

Add to cart Add to wishlist

Other available formats:
eBook

Looking for an examination copy?

If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact [email protected] providing details of the course you are teaching.

Description

Contents

Resources

Courses

About the Authors

There are global concerns about the proliferation and misuse of club drugs and novel psychoactive substances, yet we know little about their harms and research on clinical management and treatment remains limited. This book fills the knowledge gap by providing a detailed overview of the research evidence available to date. The book provides a framework that allows readers to understand this large number of new drugs, using classifications based on primary psychoactive effect. Within this framework, the book provides detailed reviews of the more commonly used drugs. Each chapter explores pharmacology, patterns and mode of use, acute and chronic harms, and clinical interventions supported by research evidence. An invaluable resource for clinical staff, this book will support clinicians working in the emergency department, substance misuse and addiction services, mental health services, primary care, sexual health services and more. It will also be of interest to academics and those developing drug policy.
- Tackles a global public health issue and clinical challenges of rapidly changing drug patterns and limited knowledge of the harms of new psychoactive substances
- Provides a detailed summary of the up-to-date research evidence on the main club drugs and novel psychoactive substances
- Improves clinicians' ability to understand new substances that will emerge
- Offers authoritative and comprehensive guidance accessible to a wide range of clinicians and other practitioners working within substance misuse/addiction services, emergency departments, primary care, sexual health and mental health services
Read more
Reviews & endorsements
‘This book is a welcome addition to the previous 2015 NEPTUNE guidance. It provides a unique learning experience on what all clinicians should know about the misuse of club drugs and novel psychoactive substances. Capturing the latest trends of a dynamic drug market, the authors pulled together the best available evidence on a variety of substances to support the improvement of clinical practice. Whether you consult chapters of special interest or read the entire book, you can be assured that you will have been exposed to the most comprehensive work available on the clinical management of the harms of novel psychoactive substances. Highly recommended.’ Ornella Corazza, Ph.D., Professor of Addiction Science, University of Hertfordshire, UK, and President of the International Society for the Study of Emerging Drugs
‘The reader is here provided with unique, clear information on the treatment/management of NPS/club drug intake.’ Fabrizio Schifano, University of Hertfordshire, UK
See more reviews
Customer reviews

Not yet reviewed
Be the first to review

Log in to review

Review was not posted due to profanity
×

, create a review

(If you're not , sign out)

Please enter the right captcha value

Please enter a star rating.

Your review must be a minimum of 12 words.

How do you rate this item?

Reviews must contain at least 12 words about the product.

×

Product details
- Date Published: October 2022
- format: Paperback
- isbn: 9781009182133
- length: 384 pages
- copublisher: The Royal College of Psychiatrists
- dimensions: 245 x 187 x 18 mm
- weight: 0.68kg
- availability: Available
Table of Contents
1. An Introduction to Club Drugs and Novel psychoactive substances
2. Psychosocial interventions for club drugs and novel psychoactive substances
3. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) Drug group: depressants
4. New Benzodiazepine (BZD) NPS
5. Synthetic Opioids NPS (fentanyl and non-fentanyl NPS)
6. Ketamine and other NPS with dissociative effects
7. Nitrous oxide (N2O)
8. Stimulant Club Drugs and novel psychoactive substances
9. 'Ecstasy'- MDMA, 3,4-methylenedioxymethamphetamine), MDMA analogues and drugs with similar effects
10 . Methamphetamine
11. Synthetic cathinones
12. Hallucinogenic drugs
13. Synthetic cannabinoid receptor agonists (SCRA).
Look Inside
Authors
Dima Abdulrahim, Programme Manager and Principal Researcher for the NEPTUNE Project, Central and North West London NHS Foundation Trust
Dima Abdulrahim is Programme Manager and Principal Researcher for the NEPTUNE Project and Quality Lead of the Addictions Department of Central and North West London NHS Foundation Trust. She has been working in the drug treatment field for over thirty years. She is a previous Council member of the Advisory Council on the Misuse of Drugs. She co-authored Club Drugs and Novel Psychoactive Substances: The Clinician's Handbook (Cambridge University Press, 2020) with Owen Bowden-Jones and sits on the Editorial Board of Drugs, Habits and Social Policy (formerly Drugs and Alcohol Today).
Owen Bowden-Jones, Consultant Addiction Psychiatrist, Central and North West London NHS Foundation Trust
Owen Bowden-Jones is a Consultant in Addiction Psychiatry and an Honorary Professor at University College London, UK. In 2010 he founded the Club Drug Clinic, London, an innovative service offering treatment for club drugs and novel psychoactive substances. He is Chair of the Advisory Council on the Misuse of Drugs and national clinical adviser at the Office for Health Improvement. He is also a trustee of the Society for the Study of Addiction and a board member at the International Society for the Study of Emerging Drugs. His research interests include emerging drug harms, particularly in young people.